

Tirbanibulin for Pediatric Warts

NCT06791525

Status	RECRUITING
Phase	Phase 4
Sponsor	The Skin Center Dermatology Group
Enrollment	10 participants

Key Eligibility Criteria

Inclusion (5)

- Age 8-18
- Subject and their legally authorized representative must be able to understand and be willing to adhere to all protocol requirements and voluntarily sign and date informed consent and assent for minors.
- Subject is judged to be in good health as determined by the Principal Investigator, based upon the results of the screening assessments and medical history.
- Diagnosis of warts on the hands
- Wart count on the hands and 3-10

Exclusion (5)

- Wart duration >2 years.
- More than 10 warts in non-hand areas.
- Total wart surface area on the hands bigger than 100 cm²
- Prior treatment failure with the following modalities:
 1. intralesional immunotherapy
 2. intralesional bleomycin, 5-fluorouracil, methotrexate
 3. intralesional cidofovir
 4. Any over the counter, prescription topical, or in-office procedural wart treatment within 6 weeks of baseline (Day 1)
 5. Known immuno-suppressed state due to disease or medication, medical treatment
 6. Known allergy to any component of the IP
 7. Any conditions that, in the Principal Investigator's opinion, may interfere with the course of the study

Locations (1 total)

The Skin Center Dermatology Group, New City, New York, United States